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Introduction
Dual antiplatelet therapy reduces the risk of stent-related 
and spontaneous recurrent ischaemic events among 
patients with acute coronary syndromes or stable coronary 
artery disease undergoing percutaneous coronary inter-
vention.1–4 However, dual antiplatelet therapy increases 
the risk of bleeding, which could offset the anticipat-
ed benefits of a reduction in ischaemic events.1–3,5 An 
abbreviated dual antiplatelet therapy regimen followed by 
P2Y12-receptor-antagonist mono therapy could favourably 
affect the balance between bleeding risks and ischaemic 
benefits.6
Ticagrelor is a reversible and direct-acting oral antagon-
ist of the P2Y12 receptor that provides faster, greater, and 
more consistent platelet inhibition than clopidogrel.7 In 
the PLATO trial, treatment with ticagrelor as compared 
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Summary
Background We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ticagrelor alone, 
improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens.
Methods GLOBAL LEADERS was a randomised, open-label superiority trial at 130 sites in 18 countries. Patients 
undergoing percutaneous coronary intervention with a biolimus A9-eluting stent for stable coronary artery disease or 
acute coronary syndromes were randomly assigned (1:1) to 75–100 mg aspirin daily plus 90 mg ticagrelor twice daily 
for 1 month, followed by 23 months of ticagrelor monotherapy, or standard dual antiplatelet therapy with 75–100 mg 
aspirin daily plus either 75 mg clopidogrel daily (for patients with stable coronary artery disease) or 90 mg ticagrelor 
twice daily (for patients with acute coronary syndromes) for 12 months, followed by aspirin monotherapy for 
12 months. Randomisation was concealed, stratified by centre and clinical presentation (stable coronary artery disease 
vs acute coronary syndrome), and blocked, with randomly varied block sizes of two and four. The primary endpoint at 
2 years was a composite of all-cause mortality or non-fatal centrally adjudicated new Q-wave myocardial infarction as 
assessed by a core lab in a blinded manner. The key secondary safety endpoint was site-reported bleeding assessed 
according to the Bleeding Academic Research Consortium criteria (grade 3 or 5). Analysis was by intention to treat. 
This trial is registered with ClinicalTrials.gov, number NCT01813435, and is closed to new participants, with follow-
up completed.
Findings Between July 1, 2013, and Nov 9, 2015, 15 968 participants were randomly assigned, 7980 to the experimental 
group and 7988 to the control group. At 2 years, 304 (3·81%) participants in the experimental group had died or had a 
non-fatal centrally adjudicated new Q-wave myocardial infarction, compared with 349 (4·37%) participants in the control 
group (rate ratio 0·87 [95% CI 0·75–1·01]; p=0·073]). There was no evidence for a difference in treatment effects for the 
primary endpoint across prespecified s ubgroups o f a cute c oronary s yndromes a nd s table c oronary a rtery d isease 
(p=0·93). Grade 3 or 5 bleeding occurred in 163 participants in the experimental group and 169 in the control group 
(2·04% vs 2·12%; rate ratio 0·97 [95% CI 0·78–1·20]; p=0·77).
Interpretation Ticagrelor in combination with aspirin for 1 month followed by ticagrelor alone for 23 months was not 
superior to 12 months of standard dual antiplatelet therapy followed by 12 months of aspirin alone in the prevention 
of all-cause mortality or new Q-wave myocardial infarction 2 years after percutaneous coronary intervention.
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with clopidogrel (both given in combination with aspirin) 
significantly r educed t he r ate o f m ajor a dverse c ardiac 
events and all-cause mortality.7 It has been suggested 
by Mahaffey a nd c olleagues8 t hat a  d aily a spirin d ose 
of 150 mg or higher could attenuate the therapeutic 
effect o f t icagrelor. W e h ypothesised t hat t he u se o f 
ticagrelor without concomitant aspirin could preserve 
ischaemic protection while potentially avoiding bleeding 
complications.
The GLOBAL LEADERS trial was designed to compare 
the benefits and risks of 2 years of treatment with 90 mg 
ticagrelor twice daily (in combination with aspirin for the 
first month) with conventional 1-year dual antiplatelet 
therapy followed by aspirin alone in patients undergoing 
percutaneous coronary intervention with uniform use of 
an intravenous direct thrombin inhibitor and biodegrad-
able polymer biolimus-eluting stents.9
Methods
Study design and participants
GLOBAL LEADERS was an open-label, randomised 
superiority trial done at 130 sites in 18 countries, the 
design of which was described previously (appendix).9 
The study population consisted of patients scheduled to 
undergo percutaneous coronary intervention for stable 
coronary artery disease or acute coronary syndromes 
Research in context
Evidence before this study
We searched PubMed and ISI Web of Science with the terms 
((“All-comer patients” OR, “all-comers”) AND “percutaneous 
coronary intervention”) OR ((ticagrelor OR clopidogrel OR 
antiplatelet OR aspirin) AND “secondary prevention”)) for reports 
published in English before July 1, 2018, of all-comers 
percutaneous coronary intervention trials and comparative 
effectiveness studies in which an established antiplatelet strategy 
was compared with a ticagrelor-based strategy  (appendix). We 
did not find any randomised long-term outcome trials comparing 
standard dual antiplatelet therapy with an experimental ticagrelor 
regimen or any other potent P2Y12 receptor antagonist without 
aspirin in patients after implantation of a drug-eluting stent. 
We identified four randomised large outcome trials of ticagrelor 
alone or in combination with aspirin across a wide range of 
cardiovascular indications, with follow-up ranging from 90 days 
to 3 years. In PLATO, clopidogrel plus aspirin was compared with 
ticagrelor plus aspirin in 18 624 patients with acute coronary 
syndromes, with or without ST-segment elevation. The primary 
endpoint, a composite of death from cardiovascular causes or 
cerebrovascular causes or any death without another known 
cause, occurred significantly less often in the ticagrelor group 
than in the clopidogrel group (9·8% vs 11·7% at 12 months; 
hazard ratio [HR] 0·84 [95% CI 0·77–0·92]; p<0·001). The overall 
risk of major bleeding did not differ significantly between groups, 
but bleeding associated with non-coronary artery bypass grafting 
was significantly more common in the ticagrelor group than in 
the clopidogrel group at 12 months (4·5% vs 3·8%; p=0·03). 
In PEGASUS-TIMI 54, two doses of ticagrelor (60 mg and 90 mg) 
were compared with aspirin in 21 162 high-risk patients 
(eg, patients with diabetes, renal disease, multivessel disease, or 
recurrent myocardial infarction) who had a myocardial infarction 
at least 1 year before the trial. Compared with placebo, both doses 
of ticagrelor were associated with at least a 15% decrease in the 
frequency of the primary endpoint of death from cardiovascular 
causes, myocardial infarction, or stroke (p=0·008 for the 90 mg 
dose and p=0·004 for the 60 mg dose). However, ticagrelor 
treatment also increased the frequency of clinically significant 
bleeding complications by a factor of 2·3–2·7 (p<0·001 for each 
dose vs placebo). In EUCLID, a trial of 13 885 patients with 
symptomatic peripheral artery disease, ticagrelor monotherapy 
was not superior to clopidogrel monotherapy for the reduction of 
cardiovascular events—a composite of cardiovascular death, 
myocardial infarction, or ischaemic stroke (10·8% vs 10·6%; 
HR 1·02 [95% CI 0·92–1·13]; p=0·65). Major bleeding occurred at 
a similar frequency in both groups (HR 1·10 [95% CI 0·84–1·43]; 
p=0·49). In the SOCRATES trial of 13 199 patients with a 
non-severe ischaemic stroke or high-risk transient ischaemic 
attack who had not received intravenous or intra-arterial 
thrombolysis and were not judged to have had a cardioembolic 
stroke, ticagrelor was not superior to aspirin in reducing the rate 
of stroke, myocardial infarction, or death at 90 days. Again, 
the frequency of major bleeding occurred was similar in the 
two treatment groups (HR 0·83 [95% CI 0·52–1·44]). Other trials 
investigating an aspirin-free strategy in patients not on oral 
anticoagulants include GEMINI-ACS-1 and COMPASS, in which 
aspirin was replaced with a direct factor Xa inhibitor rather than a 
potent P2Y12 inhibitor.
Added value of this study
To our knowledge, GLOBAL LEADERS is the largest trial so far of 
1 month of dual antiplatelet therapy with aspirin and ticagrelor 
followed by ticagrelor monotherapy versus a standard dual 
antiplatelet regimen after implantation of a drug-eluting stent. 
The sole use of ticagrelor, a P2Y12 receptor antagonist, as an 
antiplatelet regimen rather than aspirin after cessation of dual 
anti-platelet therapy was a unique aspect of the study. GLOBAL 
LEADERS is the only randomised trial so far in which 
randomisation was done at percutaneous coronary 
intervention and in which two antiplatelet strategies were 
compared, with up to 2 years of follow-up.
Implications of all the available evidence
Ticagrelor in combination with aspirin for 1 month followed by 
ticagrelor alone was not superior to 1 year of standard dual 
antiplatelet therapy followed by aspirin alone in the prevention 
of all-cause mortality or new Q-wave myocardial infarction at 
2 years after percutaneous coronary intervention. The frequency 
of major bleeding according to the Bleeding Academic Research 
Consortium criteria was similar between groups. Overall, our 
data do not support a change to standard clinical practice. 
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who required dual antiplatelet therapy, unless oral 
anticoagulation was indicated.9 The full inclusion and 
exclusion criteria are in the appendix. The trial was 
approved by the institutional review board at each 
participating institution. The study adhered to the ethical 
principles of the Declaration of Helsinki, to specifications 
of the International Conference of Harmonisation, and 
to Good Clinical Practice. All participants provided 
written informed consent at enrolment. An independent 
data and safety monitoring committee oversaw the safety 
of all patients. Our trial protocol is in the appendix.
Randomisation and masking
After diagnostic coronary angiography but before percut-
aneous coronary intervention, eligible patients were 
centrally randomised (1:1) to either the experimental 
treatment or the control treatment. Randomisation was 
concealed via a locked web-based system from study 
nurses and physicians enrolling patients. The allocation 
sequence was computer generated by an external pro-
grammer who was not otherwise involved in the trial, 
stratified by centre and clinical presentation (stable 
coronary artery disease vs acute coronary syndrome), and 
blocked, with randomly varied block sizes of two and 
four. GLOBAL LEADERS was an open-label trial.
Procedures
After diagnostic coronary angiography, percutaneous cor-
onary intervention was standardised by uniform implanta-
tion of biodegradable polymer-based biolimus A9-eluting 
stents and bivalirudin administration whenever indica-
ted or feasible. There were no restrictions on the number 
of treated lesions or vessels, lesion length, or number 
of stents used. Antiplatelet therapy was started before or 
at the time of the index procedure. Patients in the 
experimental treatment group took 75–100 mg aspirin 
Figure 1: Trial profile
In patients with repeat revascularisation, the allocated initial dual antiplatelet regimen could be resumed for 30 days after revascularisation in patients allocated to 
the experimental treatment group and for 365 days after revascularisation in patients allocated to the control group. *Includes people who did not receive the correct 
allocated intervention. †Includes five participants for whom vital status information was not available at 2 years (these patients were censored at timepoint of last 
available follow-up). ‡Includes three participants for whom vital status information was not available at 2 years (these patients were censored at timepoint of last 
available follow-up).
7999 allocated to control 
group
221 did not receive allocated intervention
142 received other dual antiplatelet 
therapy
54 received aspirin monotherapy
20 received ticagrelor and aspirin not 
in accordance with protocol 
2 received ticagrelor monotherapy
2 received clopidogrel monotherapy
1 received no antiplatelet 
therapy 
11 withdrew consent or objected to 
further use of data 
770 did not finish control regimen*
213 received clopidogrel and aspirin
54 received ticagrelor and aspirin
126 received no antiplatelet treatment
110 received clopidogrel monotherapy   
7 received ticagrelor monotherapy
7 received other P2Y12 antagonist 
and aspirin
253 died
237 unknown whether experimental 
regimen completed
7988 continued in control
group
7767 received allocated 
intervention
6981 completed treatment
7988 analysed for primary 
endpoint‡
7980 analysed for primary 
endpoint†
15 991 participants recruited and randomly assigned
7992 allocated to 
experimental group
7980 continued in 
experimental group 198 did not receive allocated intervention
149 received other dual antiplatelet 
therapy
41 received aspirin monotherapy 
4 received no antiplatelet
 treatment
3 received other P2Y12 antagonist 
monotherapy
1 received ticagrelor monotherapy
12 withdrew consent or objected to 
further use of data 
1902 did not finish experimental regimen*
1015 received aspirin monotherapy   
137 received ticagrelor and aspirin
186 received other P2Y12 
antagonist and aspirin 
194 received no antiplatelet 
treatment
146 received other P2Y12 
antagonist monotherapy
224 died
268 unknown whether experimental 
regimen completed
7782 received allocated 
intervention
5810 completed 
experimental treatment  
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daily in combination with 90 mg ticagrelor twice daily for 
1 month, followed by 90 mg ticagrelor twice daily for 
23 months, irrespective of clinical presentation. Patients 
in the control group received standard treatment: 
12 months of dual antiplatelet therapy consisting of 
75–100 mg aspirin daily in combination with either 75 mg 
clopidogrel daily (for patients with stable coronary artery 
disease) or 90 mg ticagrelor twice daily (for patients with 
acute coronary syndromes), followed by 75–100 mg aspirin 
daily for 12 months. Loading doses were given as 
previously des cribed.9 Trial medications were dispensed 
every 3 months during direct patient contact. Adherence 
was assessed by direct pill counts and self-reporting. 
Adherence counselling by the study team was the default 
strategy to improve drug adherence.
Follow-up visits were scheduled at 30 days and 
3, 6, 12, 18, and 24 months after the index procedure. The 
protocol mandated that a 12-lead electrocardiogram (ECG) 
was obtained at discharge, 3 months, and 2 years, and 
intercurrently in the case of revascularisation procedures 
or suspected ischaemic events. ECG analyses were 
done in a central core laboratory (Cardialysis, Rotterdam, 
Netherlands) by staff w ho w ere u naware o f g roup 
assignments. The electronic case report form was revised 
and implemented on Aug 28, 2013, to enable ascertainment 
of reasons for non-adherence to the allocated strategy 
during all visits.
Outcomes
The primary endpoint was a composite of all-cause death 
or new Q-wave myocardial infarction within 730 days of 
the index procedure. Deaths from any cause were 
ascertained without adjudication.10 Q-wave myocardial 
infarction was centrally adjudicated and defined accord-
ing to the Minnesota classification ( new m ajor Q -QS 
wave abnormalities) or by the appearance of a new left 
bundle branch block in conjunction with abnormal bio-
markers (appendix).11,12 The key secondary safety endpoint 
was site-reported bleeding assessed according to the 
Bleeding Academic Research Consortium (BARC) criteria 
(grade 3 or 5).13 Other secondary endpoints included 
the individual components of the primary endpoint; 
a composite endpoint of all-cause death, new Q-wave 
myocardial infarction, or stroke; myocardial infarction; 
stroke; target vessel or any revascularisation; and definite 
stent thrombosis.9 As many as seven on-site monitoring 
visits were done at individual sites, with 20% of reported 
events checked against source documents. Additionally, 
the trial was monitored for event under-reporting and 
event definition consistency. No independent adjudication 
of clinical events was implemented. Detailed definitions 
of the endpoints are in the appendix.
Statistical analysis
The rate of the primary endpoint at 2 years in the control 
group was assumed to be 5% on the basis of the results of 
the LEADERS trial.14 The PLATO trial showed a 
significant 
reduction in all-cause mortality with ticagrelor compared 
with clopidogrel (4·5% vs 5·9%; hazard ratio 0·78 [95% CI 
0·69–0·89]; p<0·001).7 We anticipated that the difference 
in our trial could be similar or even larger because of the 
potential interaction of aspirin and ticagrelor, and used a 
20% relative risk reduction as a conservative and clinically 
relevant margin.8 We estimated that a sample size of 
8000 patients per group would provide 84% power to 
detect a 20% relative risk reduction at a two-sided α 
of 0·05.
The primary endpoint was analysed by intention to 
treat with the Mantel-Cox method based on time to 
occurrence of death or diagnosis of new Q-wave 
myocardial infarction, and was reported as rate ratios 
with 95% CIs. Prespecified landmark analyses with 
cutoffs at 30 days (corresponding to the planned date of 
discontinuation of aspirin in the experimental group) 
and 1 year (corresponding to the planned dates of 
discontinuation of a P2Y12 receptor antagonist in the 
reference group) after the index procedure, with rate 
ratios calculated separately for events up to and beyond 
the landmarks. We did subgroup analyses of the primary 
Experimental intervention 
group (N=7980)
Control group 
(N=7988)
Mean age, years (SD) 64·5 (10·3) 64·6 (10·3)
Sex
Male 6115/7980 (76·6%) 6139/7988 (76·9%)
Female 1865/7980 (23·4%) 1849/7988 (23·1%)
Mean body-mass index, kg/m² (SD)* 28·2 (4·6) 28·2 (4·6)
Medical history
Diabetes mellitus 2049/7974 (25·7%) 1989/7983 (24·9%)
Insulin-dependent diabetes mellitus 606/7955 (7·6%) 617/7966 (7·7%)
Hypertension 5882/7954 (74·0%) 5833/7960 (73·3%)
Hypercholesterolaemia 5345/7718 (69·3%) 5423/7747 (70·0%)
Current smoker 2066/7980 (25·9%) 2103/7988 (26·3%)
Peripheral vascular disease 476/7904 (6.0%) 529/7918 (6·7%)
Chronic obstructive pulmonary disease 404/7947 (5·1%) 417/7949 (5·2%)
Previous major bleeding 46/7968 (0·6%) 52/7979 (0·7%)
Impaired renal function† 1099/7934 (13·9%) 1072/7949 (13·5%)
Previous stroke 210/7967 (2·6%) 211/7978 (2·6%)
Previous myocardial infarction 1831/7956 (23·0%) 1879/7966 (23·6%)
Previous percutaneous coronary intervention 2609/7974 (32·7%) 2612/7980 (32·7%)
Previous coronary artery bypass grafting 448/7974 (5·6%) 495/7981 (6·2%)
Clinical presentation
Stable coronary artery disease 4230/7980 (53·0%) 4251/7988 (53·2%)
Acute coronary syndrome
Overall 3750/7980 (47·0%) 3737/7988 (46·8%)
Unstable angina 1004/7980 (12·6%) 1018/7988 (12·7%)
Non-ST-elevation myocardial infarction 1684/7980 (21·1%) 1689/7988 (21·1%)
ST-elevation myocardial infarction 1062/7980 (13·3%) 1030/7988 (12·9%)
Data are n/N (%), unless otherwise specified. Denominators vary because medical history data were incomplete. 
*N=7979 in the intervention group and 7987 in the control group. †Defined as an estimated glomerular filtration rate 
of creatinine clearance of <60 mL/min per 1·73 m² based on the Modification of Diet in Renal Disease formula.15 
Table 1: Baseline characteristics of randomly assigned patients
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endpoint with tests for treatment-by-subgroup interaction 
by prespecified baseline character istics, and by type of 
reference treatment (use of ticagrelor vs clopidogrel) as 
a post-hoc criterion. We then did post-hoc subgroup 
analyses on the same characteristics for the key secondary 
safety endpoint of BARC grade 3 or 5 events. Secondary 
efficacy endpoints were analysed by intention to treat 
with the Mantel-Cox log-rank method up to the timepoint 
when the first event occurred (time-to-first-event 
analyses). Any subsequent events of the same type in the 
same patient were disregarded.
Categorical variables were compared with the χ² test or 
Fisher’s exact test. Continuous variables were compared 
with Student’s t test or the Wilcoxon rank-sum test for 
non-normally distributed data. Lesion data were analysed 
with mixed models accounting for lesions nested with-
in patients. All statistical analyses were done in Stata 
(version 14.2). The trial is registered with ClinicalTrials.gov, 
number NCT01813435.
Role of the funding source
The study funders had no role in trial design; data 
collection, analysis, or interpretion; or writing of the 
report. PV, MV, PJ, PWS, and SW had full access to all 
study data and had final responsibility for the decision to 
submit for publication.
Results
Between July 1, 2013, and Nov 9, 2015, we recruited and 
randomly assigned 15 991 participants, but 23 patients 
subsequently withdrew consent and requested deletion 
of their data from the database. Thus, 15 968 patients 
remained, 7980 in the experimental group and 7988 in 
the control group (figure 1). 7782 patients (97·5%) in the 
experimental group and 7767 (97·2%) in the control 
group received the allocated treatment regimen. Baseline 
clinical and procedural characteristics were well matched 
between groups (tables 1, 2). Overall 7487 (46·8%) of 
patients had acute coronary syndromes (table 1). Mean 
age was 64·5 years (SD 10·3), and 3714 (23·3%) patients 
were female (table 1). Bivalirudin-assisted percutaneous 
coronary intervention was done in 6944 (87·4%) of 
7943 patients in the experimental treatment group and 
6926 (87·2%) of 7940 patients in the control group. 
Biolimus A9-eluting stents were used in 19 415 (94·6%) 
of 20 524 lesions, and staged procedures were done in 
1455 patients (9·1%). At 2-year follow-up, vital status 
information was available for 7975 patients in the 
experimental group and 7985 patients in the control 
group (99·9% overall). ECGs were analysable in 
14 857 (93·7%) of 15 856 patients alive at 3 months and in 
14 357 (92·7%) of 15 491 patients alive at 24 months 
(appendix).
Adherence to the allocated antiplatelet treatment at 
discharge, 30 days, and 3, 6, 12, 18, and 24 months is 
shown in the appendix. In the first year of our trial, 
1378 (18%) of 7550 participants in the experimental group 
and 575 (15%) of the 3890 participants in the control 
group who had an acute coronary syndrome at baseline 
and were treated with ticagrelor did not adhere to 
tiacagrelor. At 2 years, 5810 (77·6%) of 7488 patients in 
the experimental group and 6981 (93·1%) of 7498 patients 
Experimental intervention 
group (N=7980)
Control group 
(N=7988)
Percutaneous coronary intervention done* 7943 (99·5%) 7940 (99·4%)
Vascular access site†
n 7943 7940
Radial 5872 (73·9%) 5889 (74·2%)
Femoral 2090 (26·3%) 2072 (26·1%)
Brachial 46 (0·6%) 47 (0·6%)
Lesions treated per patient
n 7907 7911
One lesion 5895 (74·6%) 5910 (74·7%)
Two lesions 1618 (20·5%) 1569 (19·8%)
Three or more lesions 394 (5·0%) 432 (5·5%)
Treated lesions‡
n (lesions) 10 403 10 438
Left main coronary artery 197 (1·9%) 190 (1·8%)
Left anterior descending artery 4283 (41·2%) 4383 (42·0%)
Left circumflex artery 2524 (24·3%) 2553 (24·5%)
Right coronary artery 3284 (31·6%) 3206 (30·7%)
Bypass graft§ 115 (1.1%) 106 (1·0%)
Stented lesions
Index percutaneous coronary intervention
n (stented lesions) 10 241 10 283
Mean stents per lesion (SD)‡ 1·2 (0·5) 1·2 (0·5)
Biolimus A9-eluting stent¶ 9708 (94·8%) 9707 (94·4%)
Other stent 654 (6·4%) 685 (6·7%)
Mean total stent length per lesion, mm (SD)‡ 24·8 (13·9) 24·8 (14·0)
Mean stent diameter per lesion, mm (SD)† 3·0 (0·5) 3·0 (0·5)
Direct stenting per lesion‡ 3334 (32·6%) 3350 (32·6%)
Bifurcation per lesion‡ 1251/10 403 (12·0%) 1265/10 438 (12·1%)
Thrombus aspiration done per lesion† 483/10 403 (4·6%) 551/10 438 (5·3%)
TIMI flow‡
Pre-procedure
n 9837 9888
0 or 1 1296 (13·2%) 1314 (13·3%)
2 1187 (12·1%) 1173 (11·9%)
3 7354 (74·8%) 7401 (74·8%)
Post-procedure
n 10 064 10 145
0 or 1 41 (0·4%) 32 (0·3%)
2 50 (0·5%) 46 (0·5%)
3 9973 (99·1%) 10 067 (99·2%)
Data are n (%) or n/N (%), unless otherwise specified. TIMI=thrombolysis in myocardial infarction.16 *85 patients did 
not undergo percutaneous coronary intervention: 64 received medical treatment only (31 in the experimental group 
and 33 in the control group) and 21 underwent urgent surgery (six in the experimental group and 15 in the control 
group). †More than one access site possible. ‡Calculated per lesion and analysed with general or generalised linear 
mixed-effects models with a random effect for patients to account for multiple lesions treated within patients. §Grafts 
counted as one separate vessel (n=221). ¶Per-protocol biolimus A9-eluting stent used; for 147 lesions (79 in the 
experimental group and 68 in the control group), both biolimus A9-eluting and other stents were implanted.
Table 2: Baseline angiographic characteristics of randomly assigned patients
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in the reference group adhered to the protocol-mandated 
antiplatelet treatment strategy. Data for 8545 consecutive 
patients who underwent the 30-day follow-up visit after 
the protocol amendment were used in the analysis of 
non-adherence. Reasons for non-adherence at 30 days, 
12 months, and 24 months are in the appendix. At all 
three timepoints, dyspnoea was a significantly more 
common reason for non-adherence in the experimental 
group than in the control group (p≤0·005; appendix).
At 2-year follow-up, a primary endpoint event—ie, 
all-cause mortality or new Q-wave myocardial infarction—
had occurred in 304 (3·81%) participants in the 
experimental group and 349 (4·37%) in the control group 
(rate ratio 0·87 [95% CI 0·75–1·01]; p=0·073; figure 2 ; 
table 3). Subclassification o f n ew Q -wave m yocardial 
infarctions according to the Minnesota code is in the 
appendix. The frequency of all-cause mortality, new 
Q-wave myocardial infarction, definite stent thrombosis, 
or investigator-reported BARC grade 3 or 5 events did not 
differ s ignificantly be tween gr oups (t able 3) . Ad ditional 
data for bleeding endpoints are in the appendix. The 
composite of all-cause death, new Q-wave myocardial 
infarction, or stroke occurred in 362 (4·54%) participants 
in the experimental group and 416 (5·21%) in the control 
group (rate ratio 0·87 [95% CI 0·76–1·00]; p=0·056; 
table 3). Dyspnoea was more common among patients 
who ever received ticagrelor (1642 [13·8%] first episodes 
among 11 936 patients ever on ticagrelor) than among 
patients who ever received clopidogrel or other P2Y12-
receptor antagonists (360 [6·5%] first e pisodes a mong 
5578 patients; p<0·0001).
Subgroup analyses showed no variation in treatment 
effects f or t he p rimary e ndpoint b y p respecified ba se-
line characteristics, or by type of reference treatment 
(use of ticagrelor vs clopidogrel) as a post-hoc criterion 
(figure 3 ). E xploratory p ost-hoc s ubgroup a nalyses o f 
BARC grade 3 or 5 events are in the appendix. A 
treatment-by-subgroup interaction was noted for type of 
indication (acute coronary syndromes vs stable coronary 
artery disease; pinteraction=0·0068), which seemed to be partly 
accounted for by a treatment-by-subgroup interaction for 
type of reference treatment (pinteraction=0·016), with an 
advantage for the experimental strategy in patients with 
acute coronary syndromes and compared against a 
ticagrelor-based reference strategy, and a disadvantage 
in patients with stable coronary artery disease and 
compared against a clopidogrel-based reference strategy. 
Landmark analyses are in the appendix. The primary 
endpoint occurred in 270 patients (3·40%) in the 
experimental group and 307 patients (3·87%) in the 
control group between 30 days and 2 years (rate ratio 
0·88 [95% CI 0·74–1·03]; p=0·115). Rates of mortality, 
myocardial infarc tion, definite s tent t hrombosis, a nd 
BARC grade 3 or 5 events were similar in both groups 
from 30 days onwards (appendix). Beyond 1 year, deaths 
from any cause were observed in 116 (1·48%) participants 
in the experimental group and 122 (1·56%) in the control 
group (rate ratio 0·95 [95% CI 0·74–1·22]; p=0·913; 
appendix). The appendix includes data for post-hoc 
composite outcomes, including net clinical benefit.
Discussion
In our multicentre randomised trial, ticagrelor in 
combination with aspirin for 1 month followed by 
ticagrelor alone for 23 months was not superior to 
standard 1-year dual antiplatelet therapy followed by 
aspirin monotherapy in terms of the composite endpoint 
of all-cause mortality or new Q-wave myocardial infarction 
after percutaneous coronary intervention. When the 
components of the primary endpoint were individually 
analysed, they did not differ significantly between groups. 
Rates of definite or probable stent thrombosis and major 
bleeding according to BARC criteria were similar between 
the groups. Rates of major bleeding were similar to those 
reported for the PRODIGY allcomers percutaneous 
coronary intervention trial.17
Although our study was not designed to assess the 
non-inferiority of the experimental treatment strategy 
compared with the current standard of care, the upper 
boundary of the 95% CI of the primary endpoint was 
close to unity, suggesting no relevant safety signal of the 
experimental strategy. In post-hoc subgroup analyses of 
bleeding events, we noted some evidence for a treatment-
by-subgroup interaction for type of indication, which 
seemed to be partly explained by an interaction with type 
of reference treatment, with an advantage for the 
experimental strategy in patients with acute coronary 
syndrome and compared against a ticagrelor-based 
reference strategy. These exploratory findings would 
need to be confirmed in future trials in patients with 
acute coronary syndromes.
Figure 2: Cumulative incidence of all-cause mortality at 2 years
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GLOBAL LEADERS is the largest trial so far testing 
1 month of dual antiplatelet therapy versus a more 
prolonged dual antiplatelet regimen after implantation of 
a drug-eluting stent. It had a unique design, in that it 
mandated monotherapy with ticagrelor, a P2Y12 receptor 
antagonist, as an antiplatelet regimen and not aspirin 
alone after cessation of dual antiplatelet therapy. Thus, 
our results cannot be extrapolated to patients receiving 
1 month of dual antiplatelet therapy followed by aspirin 
monotherapy. The duration of dual antiplatelet therapy 
in the control group was based on professional guide-
lines at the time of study design. We recognise that a 
shorter duration of dual antiplatelet therapy of 6 months 
is recommended in the 2017 European Society of 
Cardiology guidelines for patients with stable coronary 
artery disease undergoing elective percutaneous coronary 
intervention, although an extension of treatment for 
another 6 months remains an option in the absence of 
bleeding complications.18
Several studies have shown that prolonged dual 
antiplatelet therapy is associated with a trade-off between 
ischaemic and bleeding risks.1–3,5,19,20 In the dual anti platelet 
therapy study,1 prolongation of treatment for an additional 
18 months beyond 1 year significantly reduced major 
adverse cardiovascular events and stent thrombosis. 
However, all-cause mortality and rates of moderate and 
severe bleeding increased.1 There was an interaction 
between stent type and major adverse cardiovascular 
events, suggesting limited incremental benefit of extended 
dual antiplatelet therapy in patients receiving new-
generation drug-eluting stents.1 In our protocol, we 
mandated the uniform use of biolimus A9-eluting stent 
platform, which is as safe and efficacious as newer 
generation durable polymer drug-eluting stents.21 The use 
of a uniform stent avoids difficulties in interpretation 
resulting from differences in treatment effects with 
different stents, but retains generalisability in view of the 
similar performance of our stent to that of the best new-
generation drug-eluting stents.22
In the PEGASUS trial,2 in patients with a history of 
myocardial infarction at least 1 year before randomisation 
and at least one additional high-risk feature, 60 mg or 
90 mg ticagrelor twice daily significantly reduced the risk 
of the composite endpoint of cardiovascular death, 
myocardial infarction, or stroke (p=0·004 and p=0·008, 
respectively) but increased the risk of major bleeding 
(p<0·001 for both doses) compared with placebo. In an 
attempt to improve the risk–benefit ratio of ticagrelor, we 
investigated ticagrelor in combination with aspirin for 
the first month followed by long-term ticagrelor alone. 
Our trial failed to show the superiority of the experimental 
treatment strategy compared with standard therapy. 
However, it provided reassuring information with respect 
to the safety and efficacy of ticagrelor monotherapy. The 
clinical risk profile of patients included in GLOBAL 
LEADERS was lower than that of patients included in 
PEGASUS. A PEGASUS-like patient population is under 
investigation in the TWILIGHT trial23 of ticagrelor with 
aspirin or alone in high-risk patients after coronary 
intervention.
Although the rate of serious adverse events did not 
differ significantly between the two groups, dis con-
tinuation of the treatment regimen was more common 
in the experimental group than in the control group. The 
rate of discontinuation of the experimental regimen in 
our trial compared favourably to those reported in other 
large outcome trials testing ticagrelor for various indica-
tions.2,7,24,25 In the first year of our trial, non-adherence to 
ticagrelor was noted in 1953 (17%) of 11 440 patients, 
compared with 2186 (23%) of 9333 patients in the PLATO 
trial.7 The observed differences in rates of regimen 
interruption between the experimental and reference 
treatment groups after the first year could stem from the 
fact that aspirin constitutes the default (background) 
therapy for patients with established athero thrombotic 
cardio vascular disease, whereas the experimental 
treatment strategy has not been established. Additionally, 
we cannot exclude that pleiotropic effects of aspirin other 
Experimental 
treatment group 
(N=7980)
Control group 
(N=7988)
Rate ratio 
(95% CI)
p value
All-cause mortality or new Q-wave 
myocardial infarction
304 (3·81%) 349 (4·37%) 0·87 (0·75–1·01) 0·073
All-cause mortality 224 (2·81%) 253 (3·17%) 0·88 (0·74–1·06) 0·182
New Q-wave myocardial infarction* 83 (1·04%) 103 (1·29%) 0·80 (0·60–1·07) 0·14
Composite of all-cause mortality, 
stroke, or new Q-wave myocardial 
infarction
362 (4·54%) 416 (5·21%) 0·87 (0·76–1·00) 0·056
Myocardial infarction 248 (3·11%) 250 (3·13%) 1·00 (0·84–1·19) 0·98
Stroke
Overall 80 (1·00%) 82 (1·03%) 0·98 (0·72–1·33) 0·90
Ischaemic 63 (0·79%) 68 (0·85%) 0·93 (0·66–1·31) 0·68
Haemorrhagic 13 (0·16%) 9 (0·11%) 1·45 (0·62–3·39) 0·39
Undetermined 6 (0·08%) 5 (0·06%) 1·21 (0·37–3·95) 0·76
Revascularisation 739 (9·26%) 793 (9·93%) 0·93 (0·84–1·03) 0·17
Target vessel revascularisation 389 (4·87%) 442 (5·54%) 0·88 (0·77–1·01) 0·068
Definite stent thrombosis 64 (0·80%) 64 (0·80%) 1·00 (0·71–1·42) 0·98
BARC
BARC 3 or 5 bleeding 163 (2·04%) 169 (2·12%) 0·97 (0·78–1·20) 0·77
BARC 5 bleeding
Any 22 (0·28%) 24 (0·30%) 0·92 (0·52–1·64) 0·78
5b bleeding 15 (0·19%) 18 (0·23%) 0·84 (0·42–1·66) 0·61
5a bleeding 7 (0·09%) 6 (0·08%) 1·17 (0·39–3·49) 0·78
BARC 3 bleeding
Any 150 (1·88%) 159 (1·99%) 0·95 (0·76–1·18) 0·63
3c bleeding 35 (0·44%) 25 (0·31%) 1·41 (0·84–2·35) 0·19
3b bleeding 53 (0·66%) 74 (0·93%) 0·72 (0·51–1·02) 0·065
3a bleeding 77 (0·96%) 70 (0·88%) 1·10 (0·80–1·53) 0·55
Shown are the first event per event type for each patient only. Multiple events of the same type within the same patient 
are disregarded. Data were censored 730 days after index percutaneous coronary intervention. BARC=Bleeding Academic 
Research Consortium.13 *New Q-wave or equivalent left bundle branch block (n=3) as adjudicated by the core laboratory.
Table 3: Primary and prespecified secondary outcomes
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than the antiplatelet effect could be beneficial and could 
have affected the outcome of our trial.4
Our trial has several limitations. GLOBAL LEADERS 
was an open-label trial, and thus participants and 
investigators were not masked to the components of the 
treatment strategy. Efforts t hat w ere m ade t o m inimise 
biases included a focus on major, objective outcomes 
(ie, all-cause death and centrally adjudicated Q-wave 
myocardial infarction diagnosed by blinded staff at a core 
lab). All-cause mortality is a reliable endpoint that does 
not require adjudication. Vital status was obtained in 
all but eight patients. The appearance of a new Q-wave 
on a 12-lead ECG, scrutinised by staff a t a  d edicated 
core laboratory using the Minnesota Classification, i s 
associated with an increased risk of all-cause death and 
heart failure among affected patients.26 –28 Non-fatal, new 
Q-wave myocardial infarctions constituted 186 (37%) of 
the 498 site-reported myocardial infarctions in the trial 
(table 3). The proportion of 3-month and 2-year ECGs that 
could not be analysed was higher than anticipated (5%), 
but balanced between both groups. Investigator reporting 
was used without central adjudication to ascertain 
secondary outcomes. Bias and random misclassification 
can therefore not be excluded for these outcomes. 
However, our trial was monitored for event under-
reporting and consistency of event definitions. The rate of 
all-cause mortality and the composite primary endpoint
at 2 years was lower than expected, limiting the power of 
the trial. Our original sample size calculation was based 
on the LEADERS trial, in which clopidogrel was used in 
all patients.14 In our study, clopidogrel was given only to 
patients with stable coronary artery disease with planned 
elective percutan eous coronary intervention.14,23 The lower 
rates for all-cause mortality in the control group could 
reflect the treatment benefit noted for ticagrelor compared 
with clopidogrel in patients with a planned invasive 
strategy in the PLATO trial.29 Central adjudication 
and inclusion of all investigator-reported myocardial 
infarctions in the primary composite outcome might 
have increased the power of the trial, and an event-driven 
sample size consideration could have compensated 
for the lower-than-expected event rate, but resource 
limitations prevented us from using either of these 
approaches.
In conclusion, the results of the GLOBAL LEADERS 
trial do not support a change to practice at this time. 
Several trials of shortened regimens of dual antiplatelet 
therapy after stenting are underway (eg, NCT03023020, 
NCT03355742, NCT03344653, NCT03462498). In some of 
these trials, simple, validated risk scores (eg, the PRECISE-
DAPT score20 used in Master DAPT [NCT03023020]) have 
been implemented to reduce the risk of bleeding and 
establish the optimal intensity and duration of anti-
platelet therapy.
Overall
Indication
Acute coronary syndrome
Stable coronary artery disease
Age
>75 years
≤75 years
Diabetes mellitus
Yes
No
Renal failure
Yes
No
Peripheral vascular disease
Yes
No
Left main treated
Yes
No
Region
Western Europe
Eastern Europe
Rest of the world
Type of reference treatment strategy
Use of ticagrelor
Use of clopidogrel
147/3750
157/4230
93/1292
211/6688
102/2049
202/5925
79/1099
225/6881
40/476
260/7428
13/197
291/7783
226/6156
68/1502
10/322
163/4179
141/3801
169/3737
180/4251
120/1273
229/6715
126/1989
222/5994
93/1072
256/6916
44/529
295/7389
14/190
335/7798
273/6167
65/1500
11/321
186/4146
163/3842
0·86 (0·69–1·08)
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Figure 3: Subgroup analyses of all-cause mortality or non-fatal centrally adjudicated new Q-wave myocardial infarction at 2 years
Type of reference treatment strategy was a post-hoc criterion for subgroup analysis. Rate ratios and 95% CIs were estimated with the Mantel-Cox method with 
two-sided p-values from the log-rank test. All events were censored beyond 730 days. pinteraction values were calculated with approximate χ² tests for unequal rate ratios 
in the subgroups. Assumed no risk in case of missing data: diabetes (n=11), renal failure (n=85), peripheral vascular disease (n=146).
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